Marshall Stanton Sells 2,566 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 2,566 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $44.62, for a total transaction of $114,494.92. Following the completion of the sale, the senior vice president owned 61,634 shares of the company’s stock, valued at approximately $2,750,109.08. This represents a 4.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Artivion Stock Performance

AORT stock opened at $45.57 on Friday. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.04. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. The firm has a market cap of $2.16 billion, a PE ratio of -108.49 and a beta of 1.65. The business’s 50-day moving average price is $42.64 and its two-hundred day moving average price is $36.03.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The company had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. The business’s quarterly revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Institutional Investors Weigh In On Artivion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Artivion by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after buying an additional 232,424 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Artivion by 4.1% in the first quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company’s stock valued at $42,460,000 after acquiring an additional 67,327 shares during the last quarter. Next Century Growth Investors LLC increased its position in shares of Artivion by 107.6% in the first quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock valued at $25,140,000 after acquiring an additional 530,122 shares during the last quarter. Bank of America Corp DE raised its holdings in Artivion by 22.8% during the second quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after acquiring an additional 119,634 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after purchasing an additional 139,370 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AORT. Stifel Nicolaus lifted their price target on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Citizens Jmp boosted their price objective on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Citigroup reaffirmed an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. LADENBURG THALM/SH SH downgraded Artivion from a “buy” rating to a “neutral” rating and lifted their price target for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $49.11.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.